Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Justin Kline, MD, Aaron P. Rapoport, MD, Adam M. Petrich, MD, Kenneth S. Cohen, MD, Sachdev P. Thomas, MD, Sreenivasa Nattam, MD, Krishna Rao, MD, Bethany Sleckman, MD, Walter Stadler, MD, Theodore Karrison, PhD, Sonali M. Smith, MD

Blood (2016) 128 (22): 4147.

https://doi.org/10.1182/blood.V128.22.4147.4147

Published: 2016

Journal Articles

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Jatin J. Shah, MD, Rafat Abonour, MD, Brian G M Durie, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Robert M. Rifkin, MD

Blood (2014) 124 (21): 2106.

https://doi.org/10.1182/blood.V124.21.2106.2106

Published: 2014

Journal Articles

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Robert M. Rifkin, MD, Rafat Abonour, MD, Jatin J. Shah, MD, Jayesh Mehta, MD, Mohit Narang, MD, Howard R. Terebelo, DO, Cristina J Gasparetto, MD, Sachdev P. Thomas, MD, Kathleen Toomey, MD, James W Hardin, PhD, Jane Jie Lu, MS, Laurie Kenvin, BSN, RN, Shankar Srinivasan, PhD, Rosanna J. Ricafort, MD, Yasir Nagarwala, MD, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4749.

https://doi.org/10.1182/blood.V124.21.4749.4749

Published: 2014

Journal Articles

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Rafat Abonour, MD, Jatin J. Shah, M.D., Brian Durie, MD, Howard Terebelo, DO, Cristina J Gasparetto, MD, Jayesh Mehta, MD, Mohit Narang, MD, Sachdev P Thomas, MD, Kathleen Toomey, MD, Kristen A Sullivan, MBA, CCRA, Shankar Srinivasan, PhD, Yasir Nagarwala, MD, Robert M Rifkin, MD

Blood (2013) 122 (21): 3207.

https://doi.org/10.1182/blood.V122.21.3207.3207

Published: 2013

Journal Articles

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Blood (2009) 114 (22): 2081.

https://doi.org/10.1182/blood.V114.22.2081.2081

Published: 2009

NARROW

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309

Connect MM ® —the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

Response To First-Line Treatment In Stem Cell Transplant (SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled In The Connect MM Registry

Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only